(Q50574871)

15 March 2018

title

Antiviral therapy for hepatitis C in the setting of liver transplantation. (English)

1 reference

15 March 2018

main subject

liver transplantation

1 reference

Gregory T Everson

1

1 reference

15 March 2018

Clark C Kulig

series ordinal

2

1 reference

15 March 2018

publication date

1 January 2006

1 reference

15 March 2018

Current treatment options in gastroenterology

published in

1 reference

15 March 2018

volume

9

1 reference

15 March 2018

issue

6

1 reference

15 March 2018

page(s)

520-529

1 reference

15 March 2018

Preemptive therapy for hepatitis C virus after living-donor liver transplantation

cites work

1 reference

12 December 2020

Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.

1 reference

12 December 2020

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

1 reference

12 December 2020

Diagnosis, management, and treatment of hepatitis C

1 reference

12 December 2020

Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation

1 reference

12 December 2020

Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.

1 reference

12 December 2020

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination

1 reference

12 December 2020

Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.

1 reference

12 December 2020

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

1 reference

12 December 2020

Treatment of hepatitis C in patients who have decompensated cirrhosis

1 reference

12 December 2020

Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.

1 reference

12 December 2020

Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.

1 reference

12 December 2020

Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation

1 reference

12 December 2020

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

1 reference

12 December 2020

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

1 reference

12 December 2020

Recurrence of hepatitis C infection: Where are we now?

1 reference

12 December 2020

Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation

1 reference

12 December 2020

Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.

1 reference

12 December 2020

Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.

1 reference

12 December 2020

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

1 reference

12 December 2020

Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.

1 reference

12 December 2020

Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.

1 reference

12 December 2020

Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients

1 reference

12 December 2020

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

1 reference

12 December 2020

Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence

1 reference

12 December 2020

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

1 reference

12 December 2020

Course and treatment of recurrent Hepatitis C after liver transplantation.

1 reference

12 December 2020

Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome

1 reference

12 December 2020

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.

1 reference

12 December 2020

Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation

1 reference

12 December 2020

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation

1 reference

12 December 2020

Treatment of HCV infection in patients with advanced cirrhosis.

1 reference

12 December 2020

Use of growth factors with antiviral therapy for chronic hepatitis C.

1 reference

12 December 2020

Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.

1 reference

12 December 2020

Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy

1 reference

12 December 2020

Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study

1 reference

12 December 2020

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

1 reference

12 December 2020

10.1007/S11938-006-0008-5

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018